Evidence of Liver Transplantation, Myocardial Injury
Conditions
Keywords
dexmedetomidine
Brief summary
The purpose of this study was to evaluate the protective effect of dexmedetomidine on myocardial injury during liver transplantation
Detailed description
Liver transplantation surgery may lead to myocardial injury. Dexmedetomidine, a highly specific α2-adrenoeptor agonist, has sedative and analgesic properties without significant respiratory depression at the clinically approved dosage. Some investigations indicated that dexmedetomidine was able to protect the myocardium via improving the activity of Na+-K+-adenosine triphosphate enzyme and Ca2+-adenosine triphosphate, alleviating inflammation reaction and avoiding Ca2+ overload. However, the effect and the mechanism of dexmedetomidine on myocardial injury during liver transplantation remain unclear.
Interventions
DRUGDexmedetomidine
Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
DRUGNormal saline
Equal volume normal saline substitute for dexmedetomidine
Sponsors
Tianjin First Central Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* End stage liver disease scheduled for liver transplantation in Tianjin First Center Hospital
Exclusion criteria
* Pre-existing respiratory failure,renal failure,hepatic encephalopathy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peri-operative mortality | through study completion, an average of 5 weeks |
| The incidence of cardiac complications | from anesthesia induction to 24 hours after operation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evidences of Clinically Definite Myocardial Injury Confirmed by Electrochemiluminescence | before skin incision, 0.5 hour min after anhepatic, 2 hours of neohepatic stage,the end of surgery,24 hours after operation | myohemoglobin,creatine kinase isoenzyme,cardiac troponinⅠ,Heart-type fatty acid-binding protein |
Other
| Measure | Time frame | Description |
|---|---|---|
| Length of ICU stay | through study completion, an average of 5 days | — |
| length of stay | through study completion, an average of 6 weeks | from date of admission to discharge time |
Countries
China
Contacts
Primary ContactWenli Yu, PhD
Outcome results
None listed